Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: 2019-nCoV Clear all
Terminated Phase 2 Interventional Results available

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

NCT04992273
View directory record Official record
Conditions
COVID-19
Interventions
casirivimab+imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Minute to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Anaheim, California • Miami, Florida • Stony Brook, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 23, 2026, 11:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Collection of Anti-SARS-CoV-2 Immune Plasma

NCT04344977
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Torrance, California • Miami, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Jul 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

NCT04661839
View directory record Official record
Conditions
COVID-19
Interventions
COVID-HIGIV, Placebo (saline)
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 23, 2026, 11:34 AM EDT
Terminated Phase 2 Interventional Results available

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

NCT04472494
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Jul 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional Results available

A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19

NCT04646044
View directory record Official record
Conditions
Covid-19, Coronavirus Disease 2019
Interventions
Bempegaldesleukin, Standard of Care, Placebo
Drug · Other
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Hialeah, Florida • Winter Park, Florida • Mesquite, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jul 23, 2026, 11:34 AM EDT
No Longer Available No phase listed Expanded access

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

NCT05235347
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Jul 23, 2026, 11:34 AM EDT
No Longer Available No phase listed Expanded access

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

NCT04355494
View directory record Official record
Conditions
COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jul 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

NCT04779879
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab (Gen1), Sotrovimab (Gen2)
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Anniston, Alabama • Bakersfield, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 23, 2026, 11:34 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jul 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Fostamatinib for Hospitalized Adults With COVID-19

NCT04579393
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jul 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

NCT05567952
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir, placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
67
States / cities
Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jul 23, 2026, 11:34 AM EDT
Not listed No phase listed Observational

Cardiovascular Manifestations of COVID-19

NCT04335630
View directory record Official record
Conditions
Cardiovascular Diseases, COVID
Interventions
Electrocardiogram, telemetry, echocardiogram, laboratory values
Diagnostic Test
Lead sponsor
Memorial Hermann Health System
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Jul 23, 2026, 11:34 AM EDT
Completed No phase listed Observational

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

NCT04681079
View directory record Official record
Conditions
COVID-19
Interventions
albuterol sulfate (MDI), albuterol sulfate (nebulizer)
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Jul 23, 2026, 11:34 AM EDT
Terminated Phase 2 Interventional

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

NCT05785390
View directory record Official record
Conditions
COVID-19
Interventions
NP-101, Placebo
Drug · Other
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Miami, Florida • Berwyn, Illinois • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 23, 2026, 11:34 AM EDT
Withdrawn Phase 2 Interventional

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

NCT05545319
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cooperstown, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jul 23, 2026, 11:34 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 and Anti-CD14 Treatment Trial

NCT04391309
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions
anti-CD14, Placebo, remdesivir
Biological · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Sarasota, Florida • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Jul 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

NCT05541861
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg, BNT162b4 15 mcg, BNT162b4 30 mcg, BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Tempe, Arizona • Newport Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 23, 2026, 11:34 AM EDT
Terminated Phase 2 Interventional Results available

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

NCT05077969
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Jul 23, 2026, 11:34 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

NCT04389840
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions
Dociparstat sodium, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Loxahatchee Groves, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Jul 23, 2026, 11:34 AM EDT
Terminated Phase 1 Interventional Results available

Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)

NCT05027815
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Interventions
Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
Biological
Lead sponsor
Jeffrey Bluestone
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Jul 23, 2026, 11:34 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

NCT07266558
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, mRNA-1283, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
150
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 23, 2026, 11:34 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

NCT04502472
View directory record Official record
Conditions
Covid-19
Interventions
Convalescent plasma transfusion
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Jul 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults

NCT05142306
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
COVID-HIG
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 59 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898
View directory record Official record
Conditions
Covid19
Interventions
BGB-DXP593, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jul 23, 2026, 11:34 AM EDT